Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.82 |
| ▸ | CCKBR | P32239 | 8/20 | 0.82 |
| ▸ | CCKAR | P32238 | 3/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9526573 | 0.90 | SCN9A (1.00) | SCN9ACCKBRCCKARKCNH2 | |
| SCHEMBL9526577 | 0.90 | SCN9A (1.00) | SCN9ACCKBRCCKARKCNH2 | |
| SCHEMBL9526582 | 0.90 | SCN9A (1.00) | SCN9ACCKBRCCKARKCNH2 | |
| SCHEMBL7068013 | 0.90 | SCN9A (0.80) | SCN9ACCKBRCCKARKCNH2 | |
| SCHEMBL7066471 | 0.88 | SCN9A (0.80) | SCN9ACCKBRCCKAR | |
| SCHEMBL7067312 | 0.87 | CCKBR (0.73) | SCN9ACCKBRCCKAR | |
| SCHEMBL7066447 | 0.85 | SCN9A (0.80) | SCN9ACCKBRCCKAR | |
| SCHEMBL6005333 | 0.85 | SCN9A (0.88) | SCN9ACCKBRCCKARKCNH2 | |
| SCHEMBL6005336 | 0.85 | SCN9A (0.88) | SCN9ACCKBRCCKARKCNH2 | |
| SCHEMBL7066349 | 0.83 | SCN9A (0.67) | SCN9ACCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | SCN9A 143/4885CCKBR 3298/4885CCKAR 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.